Obstetrics

 
 APOSTEL VIII
 
 Dutch TRUFFLE
 
 2Close
 
 APRIL
 Highlow
 
 PC
 Quadruple P
 
 SIMPLE III
 
 Stop or Go?
 
 STRIDER
 
 SUGAR-DIP
 
 KEUZEHULP IMPLEMENTATIE
 
 INDEX
 > MOTHER
 NethOSS
 Ppromexil-III
 ALLO
 AMPHIA
 APOSTEL-I
 APOSTEL-II
 APOSTEL-III
 APOSTEL-IV
 
 Apostel VI
 ASB
 CHIPS
 DIGITAT
 ECV Implementation
 EuFis
 Fluxim
 GlucoMOMS
 HTA Longterm conseq.
 HTA Preference study
 HYPITAT
 HYPITAT-II
 HyRAS (Hypitat followup)
 Implementatie Tour
 IUPC
 PIMPP
 PPROMCerclage
 PPROMEXIL
 PreCare
 PROBAAT
 PROBAAT-II
 PROBAAT-S
 ProTWIN
 SimpleII
 STAN
 TeMpOH-1
 TeMpOH-3
 TOSTI
 TOTEM
 Triple P
 TRUFFLE
 WOMB study

 ABCD-study
 BIG CHANGE
 CAMPUR
 Cancer in pregnancy
 Doula study
 ECV tocolysis
 ECV Uterine relaxation
 EuroHeartSurvey
 FRUIT
 HP4ALL-PC
 HP4ALL-RS
 IMPACT
 INCAS
 IRIS
 Keizerlijk litteken
 MAKE
 OOPUS
 PRELHUDE
 PROMISES
 RAVEL
 SIMPLE
 STAN followup
 VET study
 VIS-project
 Wat bevalt beter
 ZAHARA II
 ZAHARA 3
 ZOBASII
 

 

Mother study

 

Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding

 

Go to the Mother website

 

Background
Nausea and vomiting in early pregnancy are common. In many cases, symptoms are mild and self-limiting. In other cases however, severe intractable vomiting called hyperemesis gravidarum (HG) can lead to dehydration, electrolyte disturbances and significant weight loss and has repeatedly been associated with poor pregnancy outcome including low birth weight. Thereby we have overwhelming evidence that poor maternal nutrition in early pregnancy has permanent detrimental effects on offspring health, primarily in the cardiometabolic disease spectrum. HG has a major impact on maternal wellbeing and quality of life, and remains the largest single cause of hospital admission in early pregnancy. Hospitalization can be required for intravenous treatment of dehydration and electrolyte imbalance. Currently women who suffer from HG do not receive any particular nutritional attention, although nasogastric tube feeding is sometimes used as treatment of last resort. However, the etiology of HG is poorly understood and at present there is no evidence on the effectiveness and efficiency for any treatment.

 

Objective

In this prospective study we aim to find out whether an early refeeding strategy can improve maternal and neonatal outcome, and reduce hospital stay.

Study design
Multi center randomized controlled trial

Study population
Patients 18 years of age or older will be eligible if they have been admitted to hospital because of HG at a gestational age between 5+0 and 19+6 weeks. A diagnosis of HG is made if excessive nausea or vomiting necessitates hospital admission.

 

Inclusion criteria

         Gestational age between 5+0 and 19+6 weeks

         Informed consent

         Women with singleton or multiple pregnancy

         Hospital admission because of HG

         First admission or readmission for HG.

 

Exclusion criteria

         Maternal age < 18 years

         Mola hydatidosa pregnancy

         Non-vital pregnancy

         Acute infection causing vomiting (e.g. acute appendicitis, pyelonephritis)

         Contra-indication for enteral tube feeding (including oesophageal varices, allergies to compounds in enteral tube mix)

         HIV infection

         Insufficient command of Dutch or English language.


Intervention

Intravenous rehydration (care as usual) versus enteral tube feeding.

 

Outcome measures
The primary maternal outcome is the Pregnancy Unique Quantification of Emesis and nausea (PUQE) score one week after randomization. The primary neonatal outcome is birth weight. Secondary outcomes will be maternal quality of life, duration of hospital stay and admission rates, maternal weight, ketonuria, neonatal morbidity, small for gestational age (SGA), prematurity, costs and molecular outcomes in umbilical cord blood and placental tissue that relate to HG.


Power/data analysis
The analysis will be by intention to treat. Based on an improvement of PUQE score >10% after tube feeding, a difference in birth weight >200gr (SD 400gr), and a possible loss to follow-up of 10%, we need a total of 120 participants (alpha error 5%, beta error 20%). The analysis will be performed by intention to treat, and stratified for center. Quality of life as well as symptoms scores will be analyzed using repeated measures analysis of variance.


Economic evaluation
We will collect data to estimate costs and cost-effectiveness, since the intervention will be more costly but might reduce hospital stay.

Time schedule
Total study time is 45 months. Preparation time 6 months, recruitment and data collection 36 months, analysis and report 3 months.

Projectleaders
Dr B.W.J. Mol, AMC Amsterdam

Dr J.A.M. van der Post, AMC Amsterdam

Dr T.J. Roseboom, AMC Amsterdam

Dr. C. Ris-Stalpers, AMC Amsterdam

Dr J.M.J. Bais, MCA Alkmaar

Dr. R.C. Painter, AMC Amsterdam


Subsidy
Foreest Medical School, MCA Alkmaar

 

Contact (researcher)

Drs. I.J. Grooten, arts-onderzoeker MCA Alkmaar

T: +316 2297 1381

E: i.j.grooten@gmail.com / mother@studies-obsgyn.nl